Dostarlimab monotherapy in mismatch repair deficient/microsatellite instability-high advanced or recurrent endometrial cancer in the Korean expanded access program

被引：0
|
作者：
Park, Soo Jin [1 ]
Lee, Yoo Young [2 ]
Kim, Kidong [3 ]
Nam, Eun Ji [4 ]
Lim, Myong Cheol [5 ]
Kim, Min Kyu [6 ]
Kim, Ki Hyung [7 ]
Kwon, Yong-Soon [8 ]
机构：
[1] Seoul Natl Univ Hosp, Obstet & Gynecol, Seoul, South Korea
[2] Sungkyunkwan Univ, Samsung Med Ctr, Gynecol Canc Ctr, Dept Obstet & Gynecol,Sch Med, Seoul, South Korea
[3] Seoul Natl Univ, Bundang Hosp, Dept Obstet & Gynecol, Seongnam Si, South Korea
[4] Yonsei Univ, Inst Womens Life Med Sci, Dept Obstet & Gynecol, Div Gynecol Oncol,Coll Med, Seoul, South Korea
[5] Natl Canc Ctr, Ctr Gynecol Canc, Goyang, South Korea
[6] Sungkyunkwan Univ, Samsung Changwon Hosp, Sch Med, Dept Obstet & Gynecol, Chang Won, South Korea
[7] Pusan Natl Univ Hosp, Obstet & Gynecol, Busan, South Korea
[8] Eulji Univ, Coll Med, Nowon Eulji Med Ctr, Dept Obstet & Gynecol, Seoul, South Korea
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2023年 / 33卷 / SUPPL_4期
关键词：
D O I：
10.1136/ijgc-2023-IGCS.230
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP134
引用
收藏
页码：A131 / A132
页数：2
相关论文
共 50 条
  • [21] Pembrolizumab in patients of Chinese descent with microsatellite instability-high/mismatch repair deficient advanced solid tumors: KEYNOTE-158
    Wu, X.
    Mao, Y.
    Xu, N.
    Bai, Y.
    Wang, D.
    Chen, X.
    Yin, X.
    Deng, Y.
    Yang, J.
    Zhang, J.
    Tang, J.
    Huang, Y.
    Li, J.
    Xu, M.
    Li, N.
    Mao, Y.
    Gozman, A.
    Xu, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S1707 - S1707
  • [22] Tislelizumab in previously treated, locally advanced unresectable/metastatic microsatellite instability-high/ mismatch repair-deficient solid tumors
    Li, Jian
    Xu, Ye
    Zang, Aimin
    Gao, Yunong
    Gao, Quanli
    Zhang, Yanqiao
    Wang, Dong
    Xu, Jianming
    Yuan, Ying
    Jiang, Haiping
    Ying, Jieer
    Shi, Chunmei
    Deng, Yanhong
    Wang, Jing
    Liu, Tianshu
    Huang, Yi
    Qian, Xiaoping
    Pan, Yueyin
    Cheng, Ying
    Hu, Sheng
    Wang, Jin
    Shi, Mengyue
    Wang, Ke
    Hu, Han
    Shen, Lin
    CHINESE JOURNAL OF CANCER RESEARCH, 2024, 36 (03)
  • [23] Tislelizumab in previously treated, locally advanced unresectable/metastatic microsatellite instability-high/mismatch repair-deficient solid tumors
    Jian Li
    Ye Xu
    Aimin Zang
    Yunong Gao
    Quanli Gao
    Yanqiao Zhang
    Dong Wang
    Jianming Xu
    Ying Yuan
    Haiping Jiang
    Jieer Ying
    Chunmei Shi
    Yanhong Deng
    Jing Wang
    Tianshu Liu
    Yi Huang
    Xiaoping Qian
    Yueyin Pan
    Ying Cheng
    Sheng Hu
    Jin Wang
    Mengyue Shi
    Ke Wang
    Han Hu
    Lin Shen
    ChineseJournalofCancerResearch, 2024, 36 (03) : 257 - 276
  • [24] Pucotenlimab in patients with advanced mismatch repair-deficient or microsatellite instability-high solid tumors: A multicenter phase 2 study
    Zhang, Bo
    Song, Yan
    Luo, Suxia
    Yin, Xianli
    Li, Enxiao
    Wang, Hui
    He, Yifu
    Liu, Zhihui
    Fan, Qingxia
    Liang, Xinjun
    Shu, Yongqian
    Liu, Yunpeng
    Xu, Nong
    Zhang, Shu
    Zhuang, Zhixiang
    Zhang, Jingdong
    Kou, Xiaoge
    Wang, Fen
    Zhu, Xiaodong
    Zeng, Shan
    Wang, Ke
    Zhong, Haijun
    Li, Shengmian
    Bai, Yuxian
    Yu, Junyan
    Dou, Yiwei
    Ma, Taiyang
    Liu, Qian
    Huang, Jing
    CELL REPORTS MEDICINE, 2023, 4 (12)
  • [25] Pembrolizumab in patients of Chinese descent with microsatellite instability-high/mismatch repair deficient advanced solid tumors: KEYNOTE-158
    Mao, Y.
    Wu, X.
    Xu, N.
    Bai, Y.
    Wang, D.
    Chen, X.
    Yin, X.
    Deng, Y.
    Yang, J.
    Zhang, J.
    Tang, J.
    Huang, Y.
    Li, J.
    Xu, M.
    Li, N.
    Mao, Y.
    Gozman, A.
    Xu, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S235 - S235
  • [26] A tale of two pathways: Review of immune checkpoint inhibitors in DNA mismatch repair-deficient and microsatellite instability-high endometrial cancers
    Liu, Ying L.
    Weigelt, Britta
    CANCER, 2024, 130 (10) : 1733 - 1746
  • [27] A Phase II Study of Avelumab Monotherapy in Patients with Mismatch Repair-Deficient/Microsatellite Instability-High or POLE-Mutated Metastatic or Unresectable Colorectal Cancer
    Kim, Jwa Hoon
    Kim, Sun Young
    Baek, Ji Yeon
    Cha, Yong Jun
    Ahn, Joong Bae
    Kim, Han Sang
    Lee, Keun-Wook
    Kim, Ji-Won
    Kim, Tae-You
    Chang, Won Jin
    Park, Joon Oh
    Kim, Jihun
    Kim, Jeong Eun
    Hong, Yong Sang
    Kim, Yeul Hong
    Kim, Tae Won
    CANCER RESEARCH AND TREATMENT, 2020, 52 (04): : 1135 - 1144
  • [28] A phase 2 study of tislelizumab monotherapy in patients with previously treated, locally advanced unresectable ormetastatic microsatellite instability-high/mismatch repair deficient solid tumors.
    Li, Jian
    Xu, Ye
    Zang, Aimin
    Gao, Yunong
    Gao, Quanli
    Zhang, Yanqiao
    Wang, Dong
    Xu, Jianming
    Yuan, Ying
    Jiang, Haiping
    Ying, Jieer
    Shi, Chunmei
    Deng, Yanhong
    Wang, Jing
    Liu, Tianshu
    Huang, Yi
    Li, Zhezhen
    Wang, Huanli
    Liu, Shou
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [29] The Prevalence and Prognosis of Microsatellite Instability-High/Mismatch Repair-Deficient Colorectal Adenocarcinomas in the United States
    Gutierrez, Catherine
    Ogino, Shuji
    Meyerhardt, Jeffrey A.
    Iorgulescu, J. Bryan
    JCO PRECISION ONCOLOGY, 2023, 7
  • [30] The Prevalence and Prognosis of Microsatellite Instability-High/Mismatch Repair-Deficient Colorectal Adenocarcinomas in the United States
    Iorgulescu, B.
    Gutierrez, C.
    Ogino, S.
    Meyerhardt, J.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2022, 24 (10): : S127 - S127
12345